Insurance Approval Delay of Biologic Therapy Dose Escalation Associated with Disease Activity in Patients with Inflammatory Bowel Disease
Author:
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,Physiology
Link
https://link.springer.com/content/pdf/10.1007/s10620-023-08098-7.pdf
Reference45 articles.
1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–1517. https://doi.org/10.1053/j.gastro.2004.01.063.
2. Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780–787. https://doi.org/10.1136/gut.2010.221127.
3. Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–65.e1–3. https://doi.org/10.1053/j.gastro.2011.10.032.
4. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357:239–250. https://doi.org/10.1056/NEJMoa062897.
5. Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96–109.e1. https://doi.org/10.1053/j.gastro.2013.06.010.
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A primer on copay accumulators, copay maximizers, and alternative funding programs;Journal of Managed Care & Specialty Pharmacy;2024-08
2. Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning;Clinical Gastroenterology and Hepatology;2024-08
3. Impact of a health-system specialty pharmacy on time to upadacitinib initiation;American Journal of Health-System Pharmacy;2024-05-13
4. The PA System: Is Prior Authorization for Dose Escalation of IBD Biologic Therapy a Tolerable Alternative or a Perpetual Annoyance?;Digestive Diseases and Sciences;2023-10-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3